Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Patrick Nachipo, David Hermann, Gerald Quinnan, Melita A. Gordon, Wesley C. Van Voorhis, Pui-Ying Iroh Tam

ABSTRACT

BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18 months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known. METHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose. DISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18 months of age. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017. More... »

PAGES

456

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6

DOI

http://dx.doi.org/10.1186/s13063-018-2846-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106325480

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30139372


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Malawi", 
          "id": "https://www.grid.ac/institutes/grid.10595.38", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nachipo", 
        "givenName": "Patrick", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bill & Melinda Gates Foundation", 
          "id": "https://www.grid.ac/institutes/grid.418309.7", 
          "name": [
            "Bill and Melinda Gates Foundation, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hermann", 
        "givenName": "David", 
        "id": "sg:person.013354566014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013354566014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Emmes Corporation", 
          "id": "https://www.grid.ac/institutes/grid.280434.9", 
          "name": [
            "Emmes Corporation, Rockville, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinnan", 
        "givenName": "Gerald", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Liverpool", 
          "id": "https://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi", 
            "University of Liverpool, Liverpool, UK", 
            "Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Melita A.", 
        "id": "sg:person.0654763303.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654763303.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Voorhis", 
        "givenName": "Wesley C.", 
        "id": "sg:person.0633073157.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633073157.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Liverpool School of Tropical Medicine", 
          "id": "https://www.grid.ac/institutes/grid.48004.38", 
          "name": [
            "University of Malawi College of Medicine, Blantyre, Malawi", 
            "Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi", 
            "Liverpool School of Tropical Medicine, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iroh Tam", 
        "givenName": "Pui-Ying", 
        "id": "sg:person.0615615045.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615615045.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0035-9203(98)90804-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013106404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1473-3099(14)70772-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021077182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkr444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027905186"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pntd.0004729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028944992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2036.2005.02394.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031393042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2334-9-195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035125355", 
          "https://doi.org/10.1186/1471-2334-9-195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.36.12.2729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036577719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkh215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037644693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/aac.00260-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039090400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m110.200501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043567876"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)11401-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053486184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083206145", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pntd.0005373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083533965"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18\u00a0months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene\u00ae), an established drug that has been used for leprosy for more than 50\u00a0years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known.\nMETHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5\u00a0days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T \u00bd) determined after the last dose.\nDISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18\u00a0months of age.\nTRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13063-018-2846-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6860279", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial", 
    "pagination": "456", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f831d8f2442fb914992a20d532d417cfb6b37f80ca474771f779bab0607b63bf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30139372"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-018-2846-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106325480"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-018-2846-6", 
      "https://app.dimensions.ai/details/publication/pub.1106325480"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T22:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000571.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13063-018-2846-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-018-2846-6'


 

This table displays all metadata directly associated to this object as RDF triples.

162 TRIPLES      21 PREDICATES      42 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-018-2846-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nb21ad9fa0c934a85ac5df2a8a146a959
4 schema:citation sg:pub.10.1186/1471-2334-9-195
5 https://app.dimensions.ai/details/publication/pub.1083206145
6 https://doi.org/10.1016/s0035-9203(98)90804-5
7 https://doi.org/10.1016/s0140-6736(02)11401-2
8 https://doi.org/10.1016/s1473-3099(14)70772-8
9 https://doi.org/10.1074/jbc.m110.200501
10 https://doi.org/10.1093/jac/dkh215
11 https://doi.org/10.1093/jac/dkr444
12 https://doi.org/10.1111/j.1365-2036.2005.02394.x
13 https://doi.org/10.1128/aac.00260-15
14 https://doi.org/10.1128/aac.36.12.2729
15 https://doi.org/10.1371/journal.pntd.0004729
16 https://doi.org/10.1371/journal.pntd.0005373
17 schema:datePublished 2018-12
18 schema:datePublishedReg 2018-12-01
19 schema:description BACKGROUND: Cryptosporidium infection and diarrhea (cryptosporidiosis) is a life-threatening infection in persons with HIV and also in children of 6-18 months of age in the developing world. To date, only nitazoxanide is licensed for treatment of cryptosporidiosis, and only in persons after the first year of life and with healthy immune systems. Clofazimine (CFZ: Lamprene®), an established drug that has been used for leprosy for more than 50 years, recently has been described as effective against Cryptosporidium in vitro and in mouse infections. The efficacy and pharmacokinetics of CFZ in vivo, in HIV-infected patients with cryptosporidial diarrhea are not known. METHODS: CRYPTOFAZ includes a randomized, double-blind, placebo-controlled study of the safety, tolerability and Cryptosporidium inhibitory activity of orally administered CFZ in subjects with HIV infection and chronic diarrhea with Cryptosporidium. An additional open label aspect of the study will compare the pharmacokinetics (PK) of orally administered CFZ in HIV-infected individuals with and without Cryptosporidium-associated diarrhea. The study will recruit a total of 66 subjects. Study participants will be given either CFZ or a placebo for 5 days while in hospital and will be followed up after discharge. Cryptosporidium will be diagnosed by quantitative PCR as the definitive test and by stool ELISA, which will also be used to quantify the shedding of Cryptosporidium in stool. PK will be studied on plasma and stool samples. Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose. DISCUSSION: This study provides an opportunity to explore a possible treatment option for HIV-infected patients with cryptosporidial diarrhea, who, as of now in Malawi and most of sub-Saharan Africa, do not have a definitive treatment apart from supportive care. The strength of this study lies in it being a randomized, double-blind, placebo-controlled trial. If shown to be effective and safe, the findings will also lay a foundation for a future study of the use of CFZ in children 6-18 months of age. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03341767 . Registered on 14 November 2017.
20 schema:genre research_article
21 schema:inLanguage en
22 schema:isAccessibleForFree true
23 schema:isPartOf Ndb09a963155447bf8c8a181876ff84d6
24 Nea85d2fa620844f9bb4d05d281691c77
25 sg:journal.1297400
26 schema:name Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial
27 schema:pagination 456
28 schema:productId N41eda284762047d8ad7b95adb5a03bb7
29 N7ab58ede0f61468ba8646a2f6bca7629
30 N89a15cf78f504cb08840753b9ef3e37b
31 Na3855b893e514f32adbaed37f04916be
32 Nefd3610b78fd4c4db4ab2f3fc694af58
33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106325480
34 https://doi.org/10.1186/s13063-018-2846-6
35 schema:sdDatePublished 2019-04-10T22:42
36 schema:sdLicense https://scigraph.springernature.com/explorer/license/
37 schema:sdPublisher N9ec4b66cd0104465b58bc082571c970c
38 schema:url https://link.springer.com/10.1186%2Fs13063-018-2846-6
39 sgo:license sg:explorer/license/
40 sgo:sdDataset articles
41 rdf:type schema:ScholarlyArticle
42 N121a3115e4e14689b44ddfe989be41fd rdf:first sg:person.0615615045.28
43 rdf:rest rdf:nil
44 N41eda284762047d8ad7b95adb5a03bb7 schema:name doi
45 schema:value 10.1186/s13063-018-2846-6
46 rdf:type schema:PropertyValue
47 N4b39673668d8441f9d5dc63803047fcf rdf:first Nf37b0342bfcd406bacec44ac0677e579
48 rdf:rest Nd17b94635c6547bca2fd67a5d0adcc83
49 N7ab58ede0f61468ba8646a2f6bca7629 schema:name readcube_id
50 schema:value f831d8f2442fb914992a20d532d417cfb6b37f80ca474771f779bab0607b63bf
51 rdf:type schema:PropertyValue
52 N7ce54a9ad1b04e2d8c94f3efb96b5634 rdf:first sg:person.013354566014.76
53 rdf:rest N4b39673668d8441f9d5dc63803047fcf
54 N89a15cf78f504cb08840753b9ef3e37b schema:name dimensions_id
55 schema:value pub.1106325480
56 rdf:type schema:PropertyValue
57 N92095aaa839f4dfabad8b2cb2534c4ce schema:affiliation https://www.grid.ac/institutes/grid.10595.38
58 schema:familyName Nachipo
59 schema:givenName Patrick
60 rdf:type schema:Person
61 N9ec4b66cd0104465b58bc082571c970c schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 N9ff85cd1cc894f489e411935ec8d4d3e rdf:first sg:person.0633073157.20
64 rdf:rest N121a3115e4e14689b44ddfe989be41fd
65 Na3855b893e514f32adbaed37f04916be schema:name pubmed_id
66 schema:value 30139372
67 rdf:type schema:PropertyValue
68 Nb21ad9fa0c934a85ac5df2a8a146a959 rdf:first N92095aaa839f4dfabad8b2cb2534c4ce
69 rdf:rest N7ce54a9ad1b04e2d8c94f3efb96b5634
70 Nd17b94635c6547bca2fd67a5d0adcc83 rdf:first sg:person.0654763303.80
71 rdf:rest N9ff85cd1cc894f489e411935ec8d4d3e
72 Ndb09a963155447bf8c8a181876ff84d6 schema:issueNumber 1
73 rdf:type schema:PublicationIssue
74 Nea85d2fa620844f9bb4d05d281691c77 schema:volumeNumber 19
75 rdf:type schema:PublicationVolume
76 Nefd3610b78fd4c4db4ab2f3fc694af58 schema:name nlm_unique_id
77 schema:value 101263253
78 rdf:type schema:PropertyValue
79 Nf37b0342bfcd406bacec44ac0677e579 schema:affiliation https://www.grid.ac/institutes/grid.280434.9
80 schema:familyName Quinnan
81 schema:givenName Gerald
82 rdf:type schema:Person
83 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
84 schema:name Medical and Health Sciences
85 rdf:type schema:DefinedTerm
86 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
87 schema:name Clinical Sciences
88 rdf:type schema:DefinedTerm
89 sg:grant.6860279 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-018-2846-6
90 rdf:type schema:MonetaryGrant
91 sg:journal.1297400 schema:issn 1468-6708
92 1745-6215
93 schema:name Trials
94 rdf:type schema:Periodical
95 sg:person.013354566014.76 schema:affiliation https://www.grid.ac/institutes/grid.418309.7
96 schema:familyName Hermann
97 schema:givenName David
98 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013354566014.76
99 rdf:type schema:Person
100 sg:person.0615615045.28 schema:affiliation https://www.grid.ac/institutes/grid.48004.38
101 schema:familyName Iroh Tam
102 schema:givenName Pui-Ying
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615615045.28
104 rdf:type schema:Person
105 sg:person.0633073157.20 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
106 schema:familyName Van Voorhis
107 schema:givenName Wesley C.
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633073157.20
109 rdf:type schema:Person
110 sg:person.0654763303.80 schema:affiliation https://www.grid.ac/institutes/grid.10025.36
111 schema:familyName Gordon
112 schema:givenName Melita A.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654763303.80
114 rdf:type schema:Person
115 sg:pub.10.1186/1471-2334-9-195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035125355
116 https://doi.org/10.1186/1471-2334-9-195
117 rdf:type schema:CreativeWork
118 https://app.dimensions.ai/details/publication/pub.1083206145 schema:CreativeWork
119 https://doi.org/10.1016/s0035-9203(98)90804-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013106404
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/s0140-6736(02)11401-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053486184
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/s1473-3099(14)70772-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021077182
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1074/jbc.m110.200501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043567876
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1093/jac/dkh215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037644693
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1093/jac/dkr444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027905186
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1111/j.1365-2036.2005.02394.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031393042
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1128/aac.00260-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039090400
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1128/aac.36.12.2729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036577719
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1371/journal.pntd.0004729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028944992
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1371/journal.pntd.0005373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083533965
140 rdf:type schema:CreativeWork
141 https://www.grid.ac/institutes/grid.10025.36 schema:alternateName University of Liverpool
142 schema:name Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
143 University of Liverpool, Liverpool, UK
144 University of Malawi College of Medicine, Blantyre, Malawi
145 rdf:type schema:Organization
146 https://www.grid.ac/institutes/grid.10595.38 schema:alternateName University of Malawi
147 schema:name University of Malawi College of Medicine, Blantyre, Malawi
148 rdf:type schema:Organization
149 https://www.grid.ac/institutes/grid.280434.9 schema:alternateName Emmes Corporation
150 schema:name Emmes Corporation, Rockville, MD, USA
151 rdf:type schema:Organization
152 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
153 schema:name University of Washington, Seattle, WA, USA
154 rdf:type schema:Organization
155 https://www.grid.ac/institutes/grid.418309.7 schema:alternateName Bill & Melinda Gates Foundation
156 schema:name Bill and Melinda Gates Foundation, Seattle, WA, USA
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.48004.38 schema:alternateName Liverpool School of Tropical Medicine
159 schema:name Liverpool School of Tropical Medicine, Liverpool, UK
160 Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
161 University of Malawi College of Medicine, Blantyre, Malawi
162 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...